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Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and
bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin.
However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high
inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within
the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of
development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with
current practice, while others switch from high to low doses after the initial phase of treatment. In this review we
assess the critical considerations for treating VTE in light of emerging clinical data for new oral agents and discuss
the merits of novel treatment regimens for patients who have experienced an episode of deep vein thrombosis or
pulmonary embolism.
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Vitamin K antagonists (VKAs) such as warfarin have
been the mainstay of treatment and secondary preven-
tion of venous thromboembolism (VTE) for many years,
and are recognised by international guidelines as the
current standard of care. VKAs usually establish an anti-
coagulant effect within 2–3 days of administration. How-
ever, because a rapid, intensive anticoagulant effect is
required, a quicker acting agent such as heparin is used
initially until the desired anticoagulant effect of the VKA
has been achieved. Guidelines on the management of
VTE recommend that administration of heparin is
started concomitantly with a VKA and discontinued
after 5 days or more, once the international normalised
ratio (INR) has been between 2.0 and 3.0 for 2 consecu-
tive days [1].* Correspondence: bastian.hass@boehringer-ingelheim.com
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reproduction in any medium, provided the orDespite the benefits offered by oral therapy, the anticoagu-
lant effect of VKA treatment is associated with significant
inter- and intra-patient variability, leading to unpredictable
results in clinical practice. In addition, VKAs have an unpre-
dictable dose–response relationship. Furthermore, regular
intensive blood monitoring is required to ensure that the
INR is maintained within the target therapeutic range (INR
2.0-3.0); under-anticoagulation can result in recurrent
thromboembolism, while over-anticoagulation increases the
risk of bleeding. Achieving a balance between the risk of re-
currence and bleeding complications is therefore a central
consideration in VTE management.
Several novel, oral anticoagulants are in development,
including dabigatran etexilate (dabigatran; a reversible
direct thrombin inhibitor) and the factor Xa inhibitors
apixaban, edoxaban and rivaroxaban. These anticoagu-
lants could provide a more predictable alternative to
VKAs and have the potential to change the recom-
mended standard for treatment of VTE.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients treated with the currently-recommended
therapeutic agents?
Data on the frequency of early recurrence of VTE (i.e.,
within 5 days of treatment initiation) are sparse and
associated with broad confidence intervals [2]. However,
clinical trials and patient registries have consistently
demonstrated that the rate of VTE recurrence is highest
immediately after the initial event and gradually
decreases over time (Figure 1) [3-5]. In one analysis of
recurrent VTE timing among 1021 patients with deep
vein thrombosis (DVT) or pulmonary embolism (PE)
who received heparin plus warfarin, there was a cluster-
ing of episodes within the first 2–3 weeks after treat-
ment initiation [6]:
 26% occurred within 7 days (cumulative incidence
1.5%)
 57% within 14 days (cumulative incidence 3.2%)
 72% within 21 days (cumulative incidence 4.1%)
Cumulative incidence of recurrence in these patients
reached a plateau of 6% at 3 months [6].
In a meta-analysis of 18 studies that addressed the
timing of recurrent VTE in patients who were continu-
ously treated with VKAs for 1–6 months after their first
thromboembolic event, the incidence of recurrence sta-
bilised approximately 9 months after the index event
and appeared to be independent of the duration of anti-
coagulant therapy [7].
The optimal duration of anticoagulant therapy is con-
troversial. According to the American College of Chest
Physicians (ACCP) guidelines, the risk of recurrence
after stopping therapy is largely determined by two fac-
tors; whether the acute episode of VTE has been effect-
ively treated and the patient’s intrinsic risk of having aFigure 1 Rates of VTE recurrence in registry patients [3-5].new episode [1]. Patients with reversible provoking risk
factors for VTE (major factors such as surgery, hospital-
isation or plaster cast immobilisation, or minor factors
such as oestrogen therapy, pregnancy or prolonged
travel, prior to the acute episode) clearly benefit from
anticoagulation for 3 months rather than shorter dura-
tions. The guidelines identify unprovoked VTE and ac-
tive cancer as the most important risk factors for
recurrence after stopping anticoagulant therapy and
patients in these categories should generally receive
longer durations of thromboprophylaxis. It is recom-
mended that the risk-to-benefit ratio of continuing long-
term anticoagulant therapy is assessed periodically in the
individual patient [1].
The pattern of recurrence following a first unprovoked
VTE is different in men and women. In a meta-analysis
of prospective studies of patients with a first VTE who
received standardised anticoagulant treatment, among
the patients with an unprovoked VTE, men were at sig-
nificantly higher risk of recurrence than women (hazard
ratio [HR] 2.2, 95% confidence interval [CI] 1.7, 2.8) [8].
It appears that the risk of developing recurrent VTE is
not related to the type of initial thromboembolic event
(i.e., DVT or PE). A systematic review showed that the
overall risk of a recurrent thromboembolic event was
not significantly different between patients presenting
with PE or DVT. It is therefore unlikely that the distri-
bution of recurrent events would be different between
these two groups of patients [9]. Analysis of patients in
the Worcester Venous Thromboembolism Study found
that those who presented with PE or isolated DVT
experienced similar rates of subsequent PE and overall
VTE in the 3-year follow-up (5.9% vs. 5.1% and 15.0%
vs. 17.9%, respectively) [10]. However, the risk of early
mortality from VTE (i.e., within 1 month) is much
greater after presenting with PE than DVT [11].
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mately three times more likely to be PE after an initial
PE (~60%) than after an initial DVT (~20%) [11,12].
This difference may justify more aggressive initial treat-
ment for patients presenting with PE [1].
How do bleeding rates vary in patients treated with
currently recommended therapeutic agents?
Bleeding is the primary complication of anticoagulant
therapy. In the earlier (placebo-controlled) trials in
patients with VTE or atrial fibrillation, major bleeding
occurred in approximately 1–1.5% of patients per year
during 3–12 months of VKA therapy compared with
0.6-1% for controls. Rates of intracranial haemorrhage
(ICH) were 0.3% and 0.1%, respectively. Thus, it is esti-
mated that treatment with VKAs increases the risk of
major bleeding by 0.3-0.5% per year and of ICH by ap-
proximately 0.2% per year compared with controls
[13-15]. However, higher major bleeding rates of 2-4%
per year have been reported during longer-term trials of
VKAs in patients with VTE [15-17]. In the VKA treat-
ment arms of recent clinical trials of VTE treatment or
secondary prevention, approximately of 2% of patients
experience major bleeding [18-22]. Recent trials in
patients with atrial fibrillation show rates of ICH of 0.7-
0.8% per year with VKA therapy [23-25].
The choice of heparin formulation, i.e., subcutaneous
weight-adjusted unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH), has no observed ef-
fect on the frequency of major bleeding [26,27]. Several
studies of VTE-treated patients have also shown a clus-
tering of bleeding events at the start (i.e., during the ini-
tial 3 months) of anticoagulant therapy [6,28-30]. This is
consistent with the hypothesis that patients with a pre-
disposition to bleeding are more likely to develop this
complication soon after anticoagulant initiation [30].
Due to their selective nature, clinical trials may, how-
ever, underestimate the frequency of bleeding, and the
incidence of bleeding is markedly greater in clinical
practice. The Worcester VTE study, a large US
community-based trial, showed major bleeding rates of
12-13% per year, and the cumulative incidence of major
bleeding was approximately 8% in the month following
initial diagnosis of VTE [31].
What are the consequences of anticoagulant-related
bleeding?
The clinical impact of anticoagulant-related bleeding
complications is often severe; as many as 11% of major
bleeding episodes are fatal within 3 months [32]. Among
17,368 patients with VTE enrolled on the Registry of
Patients with Venous Thromboembolism (RIETE), 2.3%
developed major bleeding during the first 3 months of
therapy [33]. Of those patients with bleeding episodes,5.9% re-bled within 30 days, all at the same site as the
first episode. Furthermore, 33% died within 30 days of
major bleeding, with the majority of deaths due to bleed-
ing [33]. In a meta-analysis of trials with more than 6
months’ follow-up, the case-fatality rate for major bleed-
ing was 13.4%; for intracranial bleeding, 45.8% of epi-
sodes were fatal [30].
Bleeding episodes during anticoagulant therapy are
also associated with decreased quality of life and
increased resource utilisation and costs. In a randomised
controlled trial of warfarin for the prevention of stroke
in non-rheumatic atrial fibrillation, patients taking war-
farin who had a bleeding episode had significantly lower
scores on a summary health perceptions index (p <
0.05), and significantly higher scores for health concern
and health distress (p < 0.05) compared with patients
who did not bleed [34]. Furthermore, in a model of the
costs of acute DVT treatment, minor bleeding complica-
tions were assumed to result in 1 additional day of hospi-
talisation and physician services for subsequent hospital
care, at a cost of $499 [35].
What factors are associated with unfavourable outcomes
among patients with VTE?
Many studies have investigated the factors associated
with an increased risk of VTE recurrence. The most
strongly implicated are active cancer, increased plasma
fibrin D-dimer, male sex, increasing patient age, increas-
ing body mass index, lupus anticoagulant, antiphospholi-
pid antibody, and protein C or protein S deficiency
[4,16,36-41]. Moreover, patients who experience a recur-
rence of VTE during VKA therapy have a worse progno-
sis (i.e., increased incidence of further recurrences and
bleeding) than those with new VTE or those who suf-
fered recurrence after termination of VKA therapy.
The major determinants of VKA-induced bleeding are
the intensity of the anticoagulant effect, patient charac-
teristics, concomitant use of drugs that interfere with
haemostasis and length of therapy [15]. In a multivariate
analysis of the RIETE registry, age >75 years, recent
bleeding, cancer, creatinine levels >1.2 mg/dL, anaemia,
or PE at baseline were independently associated with an
increased risk for major bleeding, but type or number of
concomitant antithrombotic agents received were not
[42]. When risk profiles were derived by assigning scores
to these factors, the incidences of major bleeding in the
first 3 months of therapy were 0.3%, 2.6% and 7.3%, in
low-, medium- and high-risk patients, respectively [42].
In patients receiving anticoagulant therapy, those with
cancer have an increased risk of bleeding complications
compared with patients without cancer [43-46]. In one
study that evaluated outcomes in 842 patients with VTE
who were treated with heparin and VKAs, 181 of whom
had cancer, the 12-month cumulative incidence of major
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that of patients without cancer (HR, 2.2; 95% CI 1.2,
4.1). Moreover, the frequency of major bleeding corre-
lated with the severity of the malignancy [45]. The inci-
dence of bleeding also varies according to the site of
cancer [45,46], with one study showing that genitourin-
ary cancers were most strongly associated with major
bleeding (HR, 4.5; 95% CI 2.1, 9.9) [45].
In patients with impaired renal function, LMWH
(which is mainly cleared by the kidneys) may bio-
accumulate and cause bleeding, although the evidence
for excluding patients with renal insufficiency is contro-
versial. Moreover, it has been reported that the risk of
major bleeding in patients with impaired renal function
is increased with both LMWH and UFH [47].
How do anticoagulant strategies differ in high-risk patient
populations?
Patients with cancer represent a population at particu-
larly high risk for VTE. Cushman et al. found the first-
year incidence of recurrent VTE in the general VTE
population was 7.7%, compared with 14.0% in patients
with cancer [37]. Among patients enrolled in the RIETE
registry, those with cancer had an increased incidence of
recurrent VTE (11.4% vs 2.1%; p < 0.001), major bleed-
ing (5.1% vs. 2.1%; p = 0.007) and mortality (20% vs
5.4%; p < 0.001), compared with patients without
cancer [48].
Management of cancer patients with VKAs can be
challenging because of the frequent use of chemotherapy
and other drugs that may affect INR control and in-
crease bleeding risk through induced thrombocytopenia,
in addition to increasing the risk of liver dysfunction
[49]. To determine whether outcomes in VTE patients
with cancer were better with LMWH monotherapy or
VKAs, a meta-analysis of five open-label secondary pre-
vention trials was performed (two each of 3 and 6
months’ duration, one unspecified). The pooled risk
ratio for VTE recurrence in patients treated with
LMWH was 0.53 (95% CI 0.36, 0.76; p = 0.007) and the
pooled relative risk for major bleeding was 0.98 (95% CI
0.49, 1.93; p = 0.95) [49]. The American Society of Clin-
ical Oncology guidelines recommend the use of LMWH
monotherapy in patients with cancer who experience
VTE, for both initial (5–10 days) and long-term (≥6
months) treatment [50].
There is also clinical interest in an effective and pre-
dictable treatment regimen for patients with more severe
VTE (e.g. acute PE), that removes the need for labora-
tory monitoring associated with VKAs and minimises
bleeding complications. Mortality from recurrent VTE is
2- to 3-fold greater after PE than DVT [9,51]. In a study
of patients with acute symptomatic PE (cancer patients
excluded), the hospital length of stay was shorter inpatients on LMWH monotherapy compared with those
receiving warfarin, although for VTE recurrence, death,
bleeding episodes or a composite of the three, there were
no significant differences between treatment groups [52].
How does treatment with novel oral anticoagulants
deviate from the established treatment paradigm?
Novel oral anticoagulants including apixaban, dabiga-
tran, edoxaban and rivaroxaban can be grouped into two
categories depending on the VTE treatment regimens
used in clinical trials.
In trials of dabigatran, patients began treatment with
heparin in addition to warfarin (or warfarin-placebo) for
at least 5 days, until the patient’s INR or sham INR
reached therapeutic levels for 2 consecutive days, at
which point dabigatran was initiated at a dose of 150 mg
twice daily (bid) [21,22]. Similarly, ongoing studies of
edoxaban begin oral administration of 60 mg once daily
(qd) following initial heparin treatment once a stable
therapeutic INR has been achieved with warfarin [53].
In the cases of rivaroxaban and apixaban, oral therapy
is initiated without concomitant heparin. In the EIN-
STEIN trials, patients began treatment with 15 mg rivar-
oxaban bid, reduced to 20 mg qd after 3 weeks [18,19].
A similar strategy is used in the AMPLIFY trial, where
the dose of apixaban is reduced from 10 mg bid to 5 mg
bid after 7 days [54].
What are the rates of bleeding and recurrence in patients
treated with novel oral anticoagulants?
Data published to date suggest that initiation of treat-
ment with heparin has a crucial role to play in minimis-
ing the early rate of VTE recurrence. In a study that
compared treatment with the pentasaccharide idrapari-
nux with standard therapy (i.e., heparin followed by
VKA) in patients with acute PE, the rates of VTE recur-
rence during the first 2 weeks of treatment favoured
standard therapy [55]. This effect was maintained
throughout the study; the odds ratio for recurrence by
day 92 was 2.14 (95% CI 1.21, 3.78), suggesting that ini-
tial heparin treatment may have a durable protective ef-
fect [55]. Results from recent trials of rivaroxaban,
where initiation of treatment with heparin did not occur
[18,19], are challenging this concept, though the evi-
dence is still too scarce to be conclusive.
Recurrence rates reported in phase III clinical trials of
novel oral anticoagulants for patients presenting with
acute VTE are shown in Table 1. Overall, the incidence
of VTE recurrence in these studies is low and not sig-
nificantly different from that in the comparator LMWH
plus VKA arms – typically 2-3% at 3 months. The cu-
mulative risk of VTE recurrence in patients presenting
with DVT and/or PE over time was similar for LMWH
plus dabigatran and LMWH plus warfarin in the RE-





Rate of VTE recurrence Rate of bleeding
Major bleeding All bleeding Major/CRNM bleeding
Schulman 2009
RE-COVER [21]
2564 6 months Dabigatran 2.4% LMWH +
VKA 2.1% Difference 0.4%
(95% CI −0.8%, 1.5%);
p < 0.001, non-inferior
HR 1.10 (95% CI 0.65, 1.84)
a Dabigatran 1.6% LMWH + VKA
1.9% HR 0.82
(95% CI 0.45, 1.48)
Dabigatran 16.1%LMWH +
VKA 21.9% HR 0.71 (95% CI
0.59, 0.85)
b Dabigatran 5.6% LMWH +
VKA 8.8% HR 0.63 (95% CI
0.47, 0.84); p = 0.002
Schulman 2011
RE-COVER II [22]
2568 6 months Dabigatran 2.4% LMWH +
VKA 2.2% Difference 0.2%
(95% CI −1.0%, 1.5%);
p < 0.0001, non-inferior
HR 1.08 (95% CI 0.64, 1.80)
a Dabigatran 1.2% LMWH + VKA
1.7% HR 0.69
(95% CI 0.36, 1.32)
Dabigatran 15.6% LMWH +




3451 3, 6 or 12
months
Rivaroxaban 2.1% LMWH +
VKA 3.0%
p < 0.001, non-inferior
HR 0.68 (95% CI 0.44, 1.04)
c Rivaroxaban 0.8% LMWH + VKA
1.2% HR 0.65 (95% CI 0.33, 1.30);
p = 0.21
d Rivaroxaban 8.1% LMWH +
VKA 8.1% HR 0.97 (95% CI
0.76, 1.22); p = 0.77
EINSTEIN-PE Investigators 2012
EINSTEIN-PE [19]
4832 3, 6 or 12
months
Rivaroxaban 2.1% LMWH +
VKA 1.8%
p = 0.003, non-inferior HR
1.12 (95% CI 0.75, 1.68)
c Rivaroxaban 1.1% LMWH + VKA
2.2%
HR 0.49 (95% CI 0.31, 0.79); p = 0.003
d Rivaroxaban 10.3% LMWH +
VKA 11.4% HR 0.90 (95% CI
0.76, 1.07); p = 0.23
CRNM, clinically relevant non-major; HR, hazard ratio; LMWH, low molecular weight heparin; VKA, vitamin K antagonist.
a: Bleeding defined as major if clinically overt and if it was associated with a fall in the haemoglobin level of at least 20 g/L, resulted in the need for transfusion of 2 or more units of red cells, involved a critical site or
was fatal.
b: Clinically relevant non-major bleeding was defined as bleeding not meeting the criteria for major bleeding but associated with spontaneous skin haematoma of at least 25 cm2, spontaneous nose bleed of more
than 5 minutes’ duration, macroscopic haematuria (spontaneous or, if associated with intervention, lasting more than 24 hours), spontaneous rectal bleeding (more than spotting on toilet paper), gingival bleeding for
more than 5 minutes, bleeding leading to hospitalisation and/or requiring surgical treatment, bleeding leading to a transfusion of less than 2 units of whole blood or red cells, or any other bleeding considered
clinically relevant by the investigator.
c: Bleeding was defined as major if it was clinically overt and associated with a fall in the haemoglobin level of 20 g/L or more, or if it led to transfusion of two or more units of red cells, or if it was retroperitoneal,
intracranial, occurred in a critical site or contributed to death.
d: Clinically relevant non-major bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, interruption or

















Hass et al. Thrombosis Journal 2012, 10:24 Page 6 of 9
http://www.thrombosisjournal.com/content/10/1/24COVER and RE-COVER II studies [21,22]. In the EIN-
STEIN studies, rivaroxaban was non-inferior to standard
therapy in terms of cumulative recurrence of VTE in
patients presenting with DVT and in patients presenting
with PE [18,19]. No data on the recurrence rates in
patients treated with edoxaban or apixaban are available,
although studies are ongoing.
According to a meta-analysis of selected trials of dabi-
gatran etexilate, there was a higher incidence of acute
coronary syndrome (ACS) or myocardial infarction (MI)
events in the dabigatran arms compared with the control
arms; however, the trials included several doses, com-
parators, indications and treatment durations [56]. These
findings were mainly driven by the large RE-LY trial in
patients with atrial fibrillation in which there were nu-
merically, but not statistically significantly, fewer MIs
with warfarin compared with dabigatran. ACS events
were also more frequent (but still < 1%) with dabigatran
than with warfarin in a trial of secondary prevention of
VTE, whereas there was no difference between dabiga-
tran and placebo during extended maintenance therapy
after VTE [57,58]. In addition, no signal for increased
ACS events was detected with dabigatran versus enoxa-
parin in pooled trials of primary VTE prevention in
patients after total hip or knee replacement [59]. This
suggests that the difference seen in the warfarin-
controlled studies may be due to a more protective effect
of warfarin rather than an adverse effect of dabigatran.
In the VTE treatment trials, the incidences of ACS
events in the dabigatran and standard therapy groups,
respectively, were 0.3% versus 0.2% in RE-COVER and
0.4% versus 0.1% in RE-COVER II [21,22]. In the
EINSTEIN-PE study, incidences of ACS were 0.6% with
rivaroxaban versus 0.9% with standard therapy [19].
Reported rates of bleeding complications in clinical
trials for the novel oral agents in development are also
shown in Table 1. Dabigatran was associated with similar
major bleeds, and significantly fewer episodes of any
bleeding compared with warfarin in the RE-COVER
study [21]. A similar pattern was observed in the RE-
COVER II study [22]. These findings are consistent with
previous data from phase III studies of dabigatran, such
as the RE-LY trial [23]. In the EINSTEIN-DVT trial,
there was no significant difference between rivaroxaban
and warfarin regarding the rate of the primary safety
endpoint (the composite of major or clinically relevant
non-major bleeding), or in the incidence of major bleed-
ing [18]. In EINSTEIN-PE, fewer major bleeding events
were observed with rivaroxaban than with standard ther-
apy, although there was no significant difference be-
tween treatment groups in terms of the composite of
major or clinically relevant non-major bleeding [19].
Without a direct comparative trial of the new oral antic-
oagulants with consistent definitions of bleeding andVTE recurrence and independent assessments of all
endpoints it is not valuable, and would have to be inter-
preted with significant caution, when attempting to de-
termine whether one drug is more effective or safe than
another.
What does the available evidence mean for the future
treatment of VTE?
To date, initial heparin followed by VKA has shown the
greatest benefit in reducing the rate of recurrent VTE. This
regimen therefore represents the current gold standard
against which any new treatment will be assessed. However,
several studies have shown that many patients experience
under- or over-anticoagulation while on VKA therapy, put-
ting them at risk of recurrent VTE or bleeding, respectively.
A recent study of discharge records for patients in the
United States hospitalised with an index VTE found that
19.8% had no INR monitoring and for those who were mon-
itored only 38.1% of INR values were within the therapeutic
range (INR 2.0-3.0) [60]. In recent clinical trials, the time
patients receiving warfarin spent in the therapeutic range is
58% in EINSTEIN-DVT and 60% in RE-COVER and the
level of anticoagulation in these patients at any given point
in the therapy is subject to uncertainty.
There is a lack of information from patients receiving
anticoagulation for VTE treatment in real-world settings.
Therefore we provide some information from other pa-
tient groups with the caveat that they do not translate
directly to patients with VTE. Several publications indi-
cate that, although good levels of anticoagulation control
can be achieved in routine practice [61,62], this is not
universal. For example, time in therapeutic range among
atrial fibrillation patients was 42.1% in ‘usual care’ (out-
side of specialist anticoagulation clinics) [63], and was
48.7% during the first 3 months of therapy after heart
valve surgery in a retrospective cohort prior to imple-
menting a trial of an ‘aggressive warfarin dosing algo-
rithm’ [64]. Further to this, registry studies of VKA use
demonstrate that only about 50% of atrial fibrillation
patients at moderate or high risk of stroke actually re-
ceive treatment with a VKA. Reasons cited by physicians
for not prescribing warfarin included previous haemor-
rhage (including ICH) while taking warfarin, falls and
patient refusal or history of non-adherence [65,66].
Consideration of clinical trial data on heparin plus
VKA should also take into account the likelihood that
anticoagulation use and control may be poorer in real-
world settings. Simply put, it is probable that event rates
reported in the heparin plus VKA arms of clinical trials
overestimate the potential performance in clinical prac-
tice. Additionally, the population of patients prescribed
VKAs will be less homogeneous than the carefully
selected clinical trial population, including a proportion
who will be VKA-naïve, and thus less likely to
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practice. While some of the factors potentially contribut-
ing to poorer anticoagulation usage, adherence and con-
trol in clinical practice compared with clinical trials may
apply equally to the novel oral anticoagulants and to
conventional therapy, others might be expected to apply
more strongly to the outcomes of conventional therapy,
namely those factors deriving from the complexity of
optimally managing VKA therapy. In this context, dem-
onstration of non-inferiority versus heparin plus VKA in
studies of novel agents could be indicative of potentially
improved outcomes in patients treated with these drugs
compared with warfarin in clinical practice. However,
there are currently no data available to evaluate this.
Dabigatran etexilate has been available for clinical use
for longer than rivaroxaban. As expected with a new
anticoagulant, several case reports of serious bleeding in
patients with atrial fibrillation who were taking dabiga-
tran have been published. However, a recent review of
post-approval safety data by the European Medicines
Agency found that the frequency of reported fatal bleed-
ings with dabigatran was significantly lower than had
been observed in clinical trials at the time of authorisa-
tion [67]. A US Food and Drug Administration safety
analysis concluded that dabigatran, used in patients with
atrial fibrillation, did not increase the risk of bleeding
compared to warfarin, and found that the combined in-
cidence of ICH and gastrointestinal bleeding for new
users of warfarin was higher than for new dabigatran
users [68]. In an observational real-world study, the effi-
cacy and safety data for dabigatran in patients who had
undergone total hip or knee replacement were also sup-
portive of the phase III trial results [69].
Bleeding complications represent the primary safety
concern for physicians treating patients with VTE. To
date, data are failing to identify significant differences in
bleeding rates in subgroups of patients who may respond
better to alternative treatment strategies. Data are also
scarce for patients at the extreme end of the spectrum
with the most severe VTE (i.e., PE). Moreover, there
remains a need to develop an effective method of linking
patient bleeding risk profiles with a range of therapeutic
options. Additional study data will help to differentiate
the risks and benefits of the different anticoagulants and
might enable identification of VTE patient subgroups
that could benefit from alternative treatments.
The risks of VTE recurrence and bleeding are highest in
the first weeks of treatment, which underscores the need
to achieve the optimal level of anticoagulation in this cru-
cial phase. Regardless of the treatment strategy, physicians
must aim to achieve an optimal balance between efficacy
and safety. A novel anticoagulant that demonstrates com-
parable efficacy in terms of VTE prevention compared
with the standard of care, but may also minimise bleedingcomplications, has the potential to change current medical
practice for the treatment of VTE.
Conclusions
Novel oral anticoagulants have demonstrated safety and
efficacy in clinical trials and could provide physicians and
patients with DVT or PE more convenient therapeutic
options. In clinical trials, on the key clinical outcomes of
VTE recurrence and bleeding, these new agents perform
similarly to the established standard of care, i.e., heparin
plus VKA. However, in real-world settings, novel agents
could produce better patient outcomes.
Some novel agents, such as rivaroxaban and apixaban,
are initiated at higher doses without heparin, but clinical
trial data have yet to confirm which patient populations
are likely to derive more or less benefit from this alterna-
tive approach, especially in the first 2 weeks of treatment.
The established treatment regimen – initial use of heparin
followed by an oral anticoagulant – may well remain the
standard of care in certain high-risk populations. However,
it remains to be seen which approach will lead to the
greatest improvements in clinical outcomes in the treat-
ment and secondary prevention of VTE.
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